The enigma of p53

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 81, Issue 1, 2016, Pages 37-40

  Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; CELL FUNCTION; DNA BINDING; DNA DAMAGE; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; HUMAN; MISSENSE MUTATION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85020989873     PISSN: 00917451     EISSN: 19434456     Source Type: Book Series    
DOI: 10.1101/sqb.2016.81.031062     Document Type: Article

References (46)

1. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. 2015. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523: 352-356
2. Alt JR, Greiner TC, Cleveland JL, Eischen CM. 2003. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22: 1442-1450
3. Aubrey BJ, Strasser A, Kelly GL. 2016. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 6: a 026062
4. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221
5. Bieging KT, Mello SS, Attardi LD. 2014. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14: 359-370
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602
7. Brosh R, Rotter V. 2009. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 9: 701-713
8. Cheok CF, Lane DP. 2016. Exploiting the p53 pathway for therapy. Cold Spring Harb Perspect Med 6: a 026310
9. D'Abramo M, Besker N, Desideri A, Levine AJ, Melino G, Chillemi G. 2016. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. Oncogene 35: 3272-3281
10. Donehower LA, Lozano G. 2009. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831-841
11. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
12. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1: 45-49
13. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767
14. Finlay CA, Hinds PW, Levine AJ. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093
15. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci 103: 3232-3237
16. Freed-PastorWA, Prives C. 2012. Mutant p53: One name, many proteins. Genes Dev 26: 1268-1286
17. Hainaut P, Pfeifer GP. 2016. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med 6: a 026179
18. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci 99: 8467-8472
19. Huang L, Yan Z, Liao X, Li Y, Yang J,Wang ZG, Zuo Y, Kawai H, Shadfan M, Ganapathy S, et al. 2011. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci 108: 12001-12006
20. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7
21. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
22. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. 1998. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci 95: 15608-15612
23. Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-16
24. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872
25. Loughery J, Meek D. 2013. Switching on p53: An essential role for protein phosphorylation? BioDiscovery 8: 1
26. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238
27. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. 2003. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472
28. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME. 2006. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16-21
29. Montes de Oca Luna R,Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206
30. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860
31. Pant V, Lozano G. 2014. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 28: 1739-1751
32. Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G. 2011. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci 108: 11995-12000
33. Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. 2016. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene doi: 10.1038/onc.2016. 111
34. Parant J, Chavez-Reyes A, Little NA, YanW, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95
35. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, et al. 2013. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24: 751-765
36. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, et al. 2010. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18: 220-230
37. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. 2011. Multiple stress signals activate mutant p53 in vivo. Cancer Res 71: 7168-7175
38. Terzian T,Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. 2007. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 27: 5479-5485
39. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. 2008. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344
40. Tollini LA, Jin A, Park J, Zhang Y. 2014. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell 26: 235-247
41. Wang S, Zhao Y, Aguilar A, Bernard D, Yang C. 2016. Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: Progress and challenges. Cold Spring Harb Perspect Med 6: a 026245
42. Wasylishen AR, Lozano G. 2016. Attenuating the p53 pathway in human cancers: Many means to the same end. Cold Spring Harb Perspect Med 6: a 026211
43. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci 103: 3226-3231
44. Xiong S, Pant V, Suh YA, Van Pelt CS,Wang Y, Valentin-Vega YA, Post SM, Lozano G. 2010. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70: 7148-7154
45. Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, Davies B, Peterse EF, Sacilotto N, Walker GJ, et al. 2013. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell 155: 410-422
46. Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. 2014. Tissue-specific and agedependent effects of global Mdm2 loss. J Pathol 233: 380-391